Role of radiation therapy in Hodgkin's lymphoma

Cancer Journal

Volumn 15, Issue 2, 2009, Pages 155-160

  Yahalom, Joachim ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Chemotherapy; Hodgkin's lymphoma; Mini radiotherapy; Radiotherapy

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL TRIAL; DISEASE CONTROL; DRUG SAFETY; HEALTH PROGRAM; HODGKIN DISEASE; HUMAN; LYMPH NODE IRRADIATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION FIELD; RADIATION INJURY; RADIATION RESPONSE; REVIEW; SALVAGE THERAPY; SECOND CANCER; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; DOXORUBICIN; HODGKIN DISEASE; HUMANS; RADIOTHERAPY; SALVAGE THERAPY; VINBLASTINE;

EID: 68049123148     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181a1437a     Document Type: Review

References (41)

1. Kaplan HS. Clinical evaluation and radiotherapeutic management of Hodgkin's disease and the malignant lymphomas. N Engl J Med. 1968;278:892-899.
2. Boice JD Jr. Second cancer after Hodgkin's disease - the price of success? J Natl Cancer Inst. 1993;85:4-5. (Pubitemid 23023209)
3. Longo DL. Hodgkin's disease: the sword of Damocles resheathed. Blood. 2004;104:3418.
4. Yahalom J. "Don't throw out the baby with the bathwater" - on optimizing cure and reducing toxicity in Hodgkin's lymphoma. J Clin Oncol. 2006;24:544-548. (Pubitemid 46630415)
5. DeVita VT Jr. Hodgkin's disease-clinical trials and travails. N Engl J Med. 2003;348:2375-2376.
6. Noordijk E, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol 2005;21(suppl 1):Abstract 6506.
7. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol. 2004;22:62-68. (Pubitemid 41095115)
8. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin's disease. Blood. 2004;104:3483-3489. (Pubitemid 39564416)
9. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634-4642.
10. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765-3771. (Pubitemid 35050830)
11. Specht L, Gray RG, Clarke MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol. 1998;16:830-843.
12. Rehan F, Brillant C, Schiltz H, et al. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin's lymphoma [abstract]. Blood. 2007;110:2320.
13. Kaplan H. The radical radiotherapy of Hodgkin's disease. Radiology. 1962;78:553-561.
14. Yahalom J. Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease. Curr Oncol Rep. 2002;4:415-423.
15. Yahalom J. Favorable early-stage Hodgkin's lymphoma. J Natl Compr Canc Netw. 2006;4:233-240.
16. Goodman KA, Toner S, Hunt M, et al. Intensity modulated radiation therapy in the treatment of lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys. 2005;62:198-206.
17. Girinsky T, Pichenot C, Beaudre A, et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys. 2006;64:218-226. (Pubitemid 41831230)
18. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94:182-192. (Pubitemid 34162752)
19. Travis LB, Hill D, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin's disease. JAMA. 2003;290:465-475. (Pubitemid 37430500)
20. Koontz B, Kirkpatrick J, Clough R, et al. Combined modality therapy versus radiotherapy alone for treatment of early stage Hodgkin's disease: cure versus complications. J Clin Oncol. 2006;24:605-611. (Pubitemid 46630423)
21. Salloum E, Doria R, Schubert W, et al. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol. 1996;14:2435-2443. (Pubitemid 26300109)
22. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004;22:2835-2841. (Pubitemid 41079901)
23. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin's lymphoma: concepts and guidelines. Radiother Oncol. 2006;79:270-277. (Pubitemid 44109907)
24. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol. 2008;26:5170-5174.
25. Hoppe RT, Advani RH, Ambinder RF, et al. Hodgkin's disease/lymphoma. J Natl Compr Canc Netw. 2008;6:594-622.
26. Schlembach PJ, Wilder RB, Jones D, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J. 2002;8:377-383.
27. Prosnitz LR, Wu JJ, Yahalom J. The case for adjuvant radiation therapy in advanced Hodgkin's disease. Cancer Invest. 1996;14:361-370. (Pubitemid 26249175)
28. Yahalom J, Ryu J, Straus DJ, et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol. 1991;9:2193-2201.
29. Brizel DM, Winer EP, Prosnitz LR, et al. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy [see comments]. Int J Radiat Oncol Biol Phys. 1990;19:535-542.
30. Fabian C, Mansfield C, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease. Ann Intern Med. 1994;120:903-912.
31. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. Inter national Database on Hodgkin's Disease Overview Study Group [see comments]. J Clin Oncol. 1998;16:818-829.
32. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003;348:2396-2406. (Pubitemid 36682818)
33. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003;21:607-614.
34. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20:630-637. (Pubitemid 34111368)
35. Chisesi T, Federico M, Levis A, et al. ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Ann Oncol. 2002;13(suppl 1):102-106. (Pubitemid 34567412)
36. Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival [see comments]. Int J Radiat Oncol Biol Phys. 1996;36:3-12.
37. Yahalom J, Gulati SC, Toia M, et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol. 1993;11:1062-1070. (Pubitemid 23163345)
38. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin's disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616-623.
39. Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol. 2004;124:645-652. (Pubitemid 38297098)
40. Goodman KA, Riedel E, Serrano V, et al. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol. 2008;26:5240-5247.
41. Yahalom J. Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin's lymphoma: a randomized study caveat. Leuk Lymphoma. 2007;48:1667-1669. (Pubitemid 47386700)